Non Hodgkin Lymphoma Clinical Trial

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin’s Lymphoma

Summary

To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan® [Rituxan® as a single agent is approved by the United States Food and Drug Administration (FDA) to treat patients with relapsed or refractory follicular NHL], has in this patient population.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Signed IRB-approved informed consent
Greater than or equal to 18 years of age
Proof of follicular lymphoma
Progressive disease requiring treatment after at least 1 prior standard therapy
Acceptable hematologic status, liver function, and renal function
Patients of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment

Exclusion Criteria:

No response to prior Rituxan® or Rituxan®-containing regimen
Presence of CLL or CNS lymphoma
Known history of HIV infection or AIDS
Prior diagnosis of aggressive NHL or mantle-cell lymphoma
Serious nonmalignant disease
Pregnant or currently breast feeding

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

90

Study ID:

NCT00048555

Recruitment Status:

Completed

Sponsor:

Biogen

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 22 Locations for this study

See Locations Near You

Research site
Birmingham Alabama, 35294, United States
Research site
Tucson Arizona, 85724, United States
Research site
Los Angeles California, 90095, United States
Research site
Newport Beach California, 92658, United States
Research site
San Diego California, 92121, United States
Research site
Aurora Colorado, 80010, United States
Research site
Washington District of Columbia, 20007, United States
Research site
Tampa Bay Florida, 33612, United States
Research site
Chicago Illinois, 60611, United States
Research site
Maywood Illinois, 60153, United States
Research site
Boston Massachusetts, 2115, United States
Research site
Detroit, Michigan, 48202, United States
Research site
Rochester Minnesota, 55905, United States
Research site
Omaha Nebraska, 68198, United States
Research site
Buffalo New York, 14263, United States
Research site
New York New York, 10021, United States
Research site
Rochester New York, 14642, United States
Research site
Durham North Carolina, 27710, United States
Research site
Philadelphia Pennsylvania, 1906, United States
Research site
Columbia South Carolina, 29210, United States
Research site
Houston Texas, 77030, United States
Research site
Charlottesville Virginia, 22908, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

90

Study ID:

NCT00048555

Recruitment Status:

Completed

Sponsor:


Biogen

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider